Poultry International - June 2017 - 6

PROPERTIES OF IBD V217 STRAIN
MAR BIARNES

2. BIG ABILITY TO BREAK MATERNAL IMMUNITY

DVM, Technical Manager CESAC

Live IBD vaccines can be categorized by their breakthrough

Veterinary School of Autonomous University of Barcelona

titer (BTT) that is a critical parameter for calculation of
optimum day of vaccination using Deventer formula (3).
The V217 is a highly immunogenic strain which exhibits a

Infectious Bursal Disease (IBD) is one of the most

BTT of 636 (9) while majority of the IBD intermediate plus

important immunosuppressive diseases and a major

vaccine strains presents BTT of 500 ELISA units (3,10). The

cause for large economic losses worldwide (1). When

vaccine strains with high BTT break through higher levels

there are evidences that field IBD pressure is high,

of maternally derived antibodies (MDA) reducing the risk

the birds should be well protected as soon as possible

of vaccine neutralization, especially high in multi origin

because the field infectious bursal disease virus (IBDV)

broiler flocks having heterogeneous MDA. Additionally,

can infect at an early age (2). In such field situation, a

such vaccines allow earlier vaccination allowing a quick

vaccination strategy based on IBD intermediate plus

induction of serological response (3). This intrinsic property

vaccines is normally advised along with strict biosecurity

related to the immunogenicity of this vaccine strain

and hygiene management (3). The success of IBD

contributes to achieve early protection.

vaccination programs depends on many factors, and
one of them is how fast the vaccine is capable to induce

3. CONTROL OF PRODUCTION PARAMETERS

protection through IBDV neutralizing antibodies. In

The form of very virulent IBD virus (vvIBDV) negatively affects

this revision we describe three properties of the live IBD
intermediate plus vaccine AviPro® IBD Xtreme based on

flock performance through lower feed consumption, weight

the V217 strain:

Vaccination with V217 strain proved to effectively control the

1. EARLY PROTECTION

loss and sudden mortality induced by the acute infection (1).
zootechnical parameters in the presence of highly virulent
IBDV infection. Experimental research demonstrated that

This IBD vaccine strain derived from the Winterfield

V217 provides protection against mortality and morbidity after

2512 is distinguished for its fast seroconversion and

a challenge with vvIBDV (11,12). Furthemore, field studies

the early induction of protection. Several research

evidenced that broiler flocks immunized with V217 showed

studies showed that V217 induces a sound immune

reduction of weight loss associated with IBDV infection as well

response characterized by early production of high

as significantly lower feed conversion rate and significantly

and homogeneous level of IBD antibody titers which

higher total income as an indirect effect due to effective

is crucial to reach effective protection against highly

protection against IBDV (12). This fact jointly with the high

virulent IBDV (4,5,6,7,8). Comparison of serological

BTT and the fast induction of neutralizing antibodies makes

profiles under laboratory conditions noticed that V217 is

this vaccine strain an optimum option to design vaccination

more efficient than other IBD intermediate plus vaccine

programs to control IBDV.

strains as it elicits significantly faster and higher IBD
humoral response (6,7,8). In addition to these findings,

REFERENCES:

such investigations identified that birds vaccinated with

1.Roser Dolç and Natalia Majó. Virus-Induced immunosuppression: Infectious Bursal Disease. In: Chapter 3,
Immunosuppressive Diseases of Poultry. Edited by Isabel M. Gimeno, Grupo Asis Biomedia, 2013, p. 67-87.
2.Control and Prevention of Infectious Bursal Disease. Guillermo Zavala. EMABRLAVP00068.
3.Golden guidelines for a successful field IBD vaccination. J.J. (Sjaak) de Wit & Teun H.F. Fabri. EMABRLAVP00068a.
4.Interactions between vaccine and field viruses: Comparative study of three commercial IBDV intermediate plus
vaccines in field conditions. Aricibasi¹, M; Block, H2 and Schroeder1. Lohmann Animal Health GmbH (1). Poultry Practice
Meyer-Block, Uelsen, Germany (2).
5. IBDV 217: The efficacy and safety of the vaccine in providing to broilers until moment of slaughter and its interaction
with other vaccinations when used under field conditions. B.Othmar, 2005. Germany. Lohmann Animal Health GmbH
(data from registration dossier).
6.Comparative serological study of AviPro® IBD Xtreme versus three competitor IBD intermediate plus vaccines. M.
Biarnes (CESAC) and M. Castells (Elanco Animal Health) (data on file)
7.Comparative study of three IBD intermediate plus vaccines in broiler chickens. M. Castells et al. Elanco Animal Health,
WPC 2016.
8.Comparative studies between different commercial types of live Infectious bursal disease [IBD] vaccine strains in Egypt.
9.Protection against vvIBD and determination of the maternal breakthrough titre in broilers via drinking water (Study
339/07). B.Othmar, 2005. Germany. Lohmann Animal Health GmbH (data from registration dossier).
10. Gumboro disease: Estimation of optimal time of vaccination by the Deventer formula. De Wit J. Animal Health
Service, Deventer.
11. IBDV217: Immunogenicity in SPF birds. B. Othmar, 2005. Germany. Lohmann Animal Health GmbH (data from
registration dossier).
12. Evaluation of performance and net income of flocks with use of different intermediate plus IBD vaccines in France.
Xavier Dubord, France. WVPAC 2013.

V217 strain present a higher seropositivity (percentage of
seropositive birds) (5,6). Field experiences support the
outcomes of these studies and reinforce that the features
of this strain allow chicken flocks to achieve early
protection against IBD (4,5).

REGISTRATIONS VARY BY COUNTRY
AviPro® IBD Xtreme: (Lyophilisate for suspension). Statement of the active substance(s): 1 dose contains: Active substance: live intermediate plus IBD (Infectious bursal disease)-Virus, strain V217, 10 1.5 - 10 3 ELD 50 / bird dose*. * ELD 50 = 50 % egg-lethal dose:
the virus titer required to cause death in 50% of the inoculated embryos. Indication(s): For active immunization of chickens with maternally derived antibodies (breakthrough titer: 636) to reduce clinical disease, weight loss and acute lesions of the bursa of
Fabricius associated with infection caused by very virulent avian Infectious Bursal Disease (IBD) viruses. Onset of protection: 2 weeks. Duration of immunity: 12 weeks based on serology. Contraindications: Do not administer to unhealthy birds. Adverse reactions:
On day 7 post-vaccination severe lymphocyte depletion is seen in the bursae of the majority of birds. Lymphocyte repopulation commences after day 7 post-vaccination but by day 28 after vaccination notable lesions still remain in the bursae of the birds. The
strain causes an average score of bursal lesion of 2.9 (out of 5 according to Ph. Eur.) at 21 days post-vaccination. If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon. Withdrawal period: Zero days.
Legal category: POM-V. USE MEDICINES RESPONSIBLY.

AviPro®, Elanco and the diagonal bar are registered trademarks owned by Elanco,
a division of Eli Lilly and Company.

GBLBRLAVP00035

Table of Contents for the Digital Edition of Poultry International - June 2017